Cyclerion Therapeutics (KRSA) Stock Price, News & Analysis

Company Overview

Cyclerion Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing medicines for serious diseases with substantial unmet medical needs. The company was established in 2019 as a spinout from Ironwood Pharmaceuticals and built its research portfolio around soluble guanylate cyclase (sGC) stimulation, a mechanism involved in regulating blood flow and cellular signaling.

Cyclerion’s development programs included olinciguat, an investigational therapy studied in sickle cell disease and other vascular conditions; praliciguat, an sGC stimulator evaluated for cardiometabolic and renal diseases; and IW-6463, a central nervous system-penetrant sGC stimulator investigated for neurological disorders. These products were investigational and had not been established as approved commercial therapies based on the company’s publicly reported development history.

The company’s activities were primarily centered on drug discovery, clinical development and strategic collaborations rather than commercialized pharmaceutical sales. Cyclerion’s programs were intended for potential use in international markets, although the company’s publicly available materials primarily described research and clinical activities rather than an established geographic commercial presence. Limited current information is available regarding its operations and leadership, and the company’s historical common-stock trading symbol was CYCN rather than the symbol cited in the request.

Key Stats

• Today's Range: $30.59 to $37.25
• 50-Day Range: N/A
• 52-Week Range: $7.19 to $59.36
• Volume: 34,799 shs
• Average Volume: 56,937 shs
• Market Capitalization: $20.74 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $49.00
• Consensus Rating: Buy

Cyclerion Therapeutics Stock Analysis - MarketRank™

Cyclerion Therapeutics scored higher than 82% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 4.3 / 5
• Analyst Rating: Buy

Consensus Rating

Cyclerion Therapeutics has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 1 strong buy rating, 2 buy ratings, 1 hold rating, and no sell ratings.

Upside Potential

Cyclerion Therapeutics has a consensus price target of $49.00, representing about 58.1% upside from its current price of $31.00.

Amount of Analyst Coverage

Cyclerion Therapeutics has only been the subject of 4 research reports in the past 90 days.

Earnings and Valuation

• Score: 0.0 / 5
• Proj. Earnings Growth: Decreasing

Earnings Growth

Earnings for Cyclerion Therapeutics are expected to decrease in the coming year, from ($5.25) to ($5.44) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Cyclerion Therapeutics is -2.67, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Cyclerion Therapeutics has a P/B Ratio of 1.91. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

Short Interest

• Score: 5.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

1.01% of the float of Cyclerion Therapeutics has been sold short.

Short Interest Ratio / Days to Cover

Cyclerion Therapeutics has a short interest ratio ("days to cover") of 0.1, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Cyclerion Therapeutics has recently decreased by 75.41%, indicating that investor sentiment is improving significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Cyclerion Therapeutics does not currently pay a dividend.

Dividend Growth

Cyclerion Therapeutics does not have a long track record of dividend growth.

News and Social Media

• Score: 4.0 / 5
• News Sentiment: 1.39

News Sentiment

Cyclerion Therapeutics has a news sentiment score of 1.39. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.56 average news sentiment score of companies.

News Coverage This Week

MarketBeat has tracked 2 news articles for Cyclerion Therapeutics this week, compared to 5 articles on an average week.

Search Interest

8 people have searched for KRSA on MarketBeat in the last 30 days.

MarketBeat Follows

3 people have added Cyclerion Therapeutics to their MarketBeat watchlist in the last 30 days.

Company Ownership

• Score: 1.4 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Cyclerion Therapeutics insiders have not sold or bought any company stock.

Percentage Held by Insiders

34.30% of the stock of Cyclerion Therapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health.

Percentage Held by Institutions

75.62% of the stock of Cyclerion Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

Company Calendar

• Today: 9/26/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: N/A
• Industry: N/A
• Sub-Industry: N/A
• Current Symbol: NASDAQ:KRSA
• CIK: 1755237
• Web: www.korsana.com
• Phone: (617) 621-7722
• Fax: N/A
• Employees: 30
• Year Founded: N/A

Price Target and Rating

• Average Price Target for Cyclerion Therapeutics: $49.00
• High Price Target: $55.00
• Low Price Target: $43.00
• Potential Upside/Downside: +58.1%
• Consensus Rating: Buy
• Rating Score (0-4): 3.00
• Research Coverage: 4 Analysts

Profitability

• EPS (Trailing Twelve Months): ($11.62)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$3.53 million
• Net Margins: -170.11%
• Pretax Margin: -353.00%
• Return on Equity: -87.96%
• Return on Assets: -74.86%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 0.82
• Quick Ratio: 0.82

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $16.20 per share
• Price / Book: 1.91

Miscellaneous

• Outstanding Shares: 669,000
• Free Float: 440,000
• Market Cap: $20.74 million
• Optionable: N/A
• Beta: 1.75